Skip to main content

10.10.2017 | Onkologie | Onlineartikel

Interview: Survival is the result of multiple treatment lines

To what extent will the data of the FLAURA trial that explored first-line use of osimertinib in patients with EGFR-mutated advanced NSCLC change clinical practice? Read more ...

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten